CHARLES RIVER LABORATORIES (CRL) Fundamental Analysis & Valuation

NYSE:CRL • US1598641074

179.58 USD
+3.89 (+2.21%)
At close: Mar 4, 2026
179 USD
-0.58 (-0.32%)
After Hours: 3/4/2026, 5:16:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CRL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall CRL gets a fundamental rating of 4 out of 10. We evaluated CRL against 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of CRL get a neutral evaluation. Nothing too spectacular is happening here. CRL has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. CRL Profitability Analysis

1.1 Basic Checks

  • In the past year CRL was profitable.
  • In the past year CRL had a positive cash flow from operations.
  • Of the past 5 years CRL 4 years were profitable.
  • CRL had a positive operating cash flow in each of the past 5 years.
CRL Yearly Net Income VS EBIT VS OCF VS FCFCRL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

1.2 Ratios

  • The Return On Assets of CRL (-2.02%) is better than 61.40% of its industry peers.
  • CRL has a Return On Equity of -4.56%. This is in the better half of the industry: CRL outperforms 61.40% of its industry peers.
  • CRL has a Return On Invested Capital of 6.60%. This is in the better half of the industry: CRL outperforms 77.19% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CRL is below the industry average of 11.61%.
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROIC 6.6%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
CRL Yearly ROA, ROE, ROICCRL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15

1.3 Margins

  • CRL's Operating Margin of 12.51% is fine compared to the rest of the industry. CRL outperforms 73.68% of its industry peers.
  • CRL's Operating Margin has declined in the last couple of years.
  • The Gross Margin of CRL (34.98%) is worse than 61.40% of its industry peers.
  • CRL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 12.51%
PM (TTM) N/A
GM 34.98%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
CRL Yearly Profit, Operating, Gross MarginsCRL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. CRL Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
  • Compared to 1 year ago, CRL has less shares outstanding
  • CRL has less shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CRL is higher compared to a year ago.
CRL Yearly Shares OutstandingCRL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CRL Yearly Total Debt VS Total AssetsCRL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

  • CRL has an Altman-Z score of 2.43. This is not the best score and indicates that CRL is in the grey zone with still only limited risk for bankruptcy at the moment.
  • CRL has a Altman-Z score of 2.43. This is in the better half of the industry: CRL outperforms 66.67% of its industry peers.
  • CRL has a debt to FCF ratio of 4.13. This is a neutral value as CRL would need 4.13 years to pay back of all of its debts.
  • CRL has a Debt to FCF ratio of 4.13. This is in the better half of the industry: CRL outperforms 73.68% of its industry peers.
  • A Debt/Equity ratio of 0.68 indicates that CRL is somewhat dependend on debt financing.
  • CRL has a Debt to Equity ratio of 0.68. This is in the lower half of the industry: CRL underperforms 71.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Altman-Z 2.43
ROIC/WACC0.64
WACC10.24%
CRL Yearly LT Debt VS Equity VS FCFCRL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.3 Liquidity

  • CRL has a Current Ratio of 1.29. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CRL (1.29) is worse than 77.19% of its industry peers.
  • CRL has a Quick Ratio of 1.02. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.02, CRL is not doing good in the industry: 77.19% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.02
CRL Yearly Current Assets VS Current LiabilitesCRL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. CRL Growth Analysis

3.1 Past

  • CRL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -0.39%.
  • CRL shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 4.78% yearly.
  • CRL shows a decrease in Revenue. In the last year, the revenue decreased by -0.85%.
  • The Revenue has been growing slightly by 6.55% on average over the past years.
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%

3.2 Future

  • Based on estimates for the next years, CRL will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.70% on average per year.
  • CRL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.26% yearly.
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CRL Yearly Revenue VS EstimatesCRL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B 4B 5B
CRL Yearly EPS VS EstimatesCRL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20 25

More info and screens

Find the best growth stocksShow best growing peers

5

4. CRL Valuation Analysis

4.1 Price/Earnings Ratio

  • CRL is valuated rather expensively with a Price/Earnings ratio of 17.47.
  • CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 91.23% of the companies in the same industry.
  • CRL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.03.
  • The Price/Forward Earnings ratio is 16.35, which indicates a correct valuation of CRL.
  • Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 91.23% of the companies are valued more expensively.
  • CRL is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 25.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 17.47
Fwd PE 16.35
CRL Price Earnings VS Forward Price EarningsCRL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 94.74% of the companies in the same industry are more expensive than CRL, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, CRL is valued cheaply inside the industry as 87.72% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.05
EV/EBITDA 11.68
CRL Per share dataCRL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.54
PEG (5Y)3.66
EPS Next 2Y8.98%
EPS Next 3Y8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRL Dividend Analysis

5.1 Amount

  • CRL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRL Fundamentals: All Metrics, Ratios and Statistics

CHARLES RIVER LABORATORIES

NYSE:CRL (3/4/2026, 5:16:54 PM)

After market: 179 -0.58 (-0.32%)

179.58

+3.89 (+2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-18
Earnings (Next)05-05
Inst Owners107.25%
Inst Owner Change3.99%
Ins Owners0.89%
Ins Owner Change4.42%
Market Cap8.84B
Revenue(TTM)4.02B
Net Income(TTM)-144.34M
Analysts78.26
Price Target206.28 (14.87%)
Short Float %6.07%
Short Ratio3.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.93%
Min EPS beat(2)0.98%
Max EPS beat(2)2.88%
EPS beat(4)4
Avg EPS beat(4)9.75%
Min EPS beat(4)0.98%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)9.14%
EPS beat(12)12
Avg EPS beat(12)7.96%
EPS beat(16)16
Avg EPS beat(16)6.74%
Revenue beat(2)1
Avg Revenue beat(2)0.06%
Min Revenue beat(2)-0.27%
Max Revenue beat(2)0.38%
Revenue beat(4)3
Avg Revenue beat(4)1.83%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)3.74%
Revenue beat(8)6
Avg Revenue beat(8)1.34%
Revenue beat(12)9
Avg Revenue beat(12)1.37%
Revenue beat(16)11
Avg Revenue beat(16)1.18%
PT rev (1m)-1.14%
PT rev (3m)6.95%
EPS NQ rev (1m)-20.71%
EPS NQ rev (3m)-21.1%
EPS NY rev (1m)-0.06%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)-0.99%
Revenue NQ rev (3m)-1.09%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 17.47
Fwd PE 16.35
P/S 2.2
P/FCF 17.05
P/OCF 11.98
P/B 2.79
P/tB 146.38
EV/EBITDA 11.68
EPS(TTM)10.28
EY5.72%
EPS(NY)10.99
Fwd EY6.12%
FCF(TTM)10.53
FCFY5.87%
OCF(TTM)14.99
OCFY8.35%
SpS81.58
BVpS64.3
TBVpS1.23
PEG (NY)2.54
PEG (5Y)3.66
Graham Number121.95
Profitability
Industry RankSector Rank
ROA -2.02%
ROE -4.56%
ROCE 8.35%
ROIC 6.6%
ROICexc 6.84%
ROICexgc 14.71%
OM 12.51%
PM (TTM) N/A
GM 34.98%
FCFM 12.91%
ROA(3y)1.3%
ROA(5y)3.17%
ROE(3y)2.98%
ROE(5y)8.14%
ROIC(3y)6.85%
ROIC(5y)7.38%
ROICexc(3y)7.1%
ROICexc(5y)7.66%
ROICexgc(3y)16.12%
ROICexgc(5y)18.95%
ROCE(3y)8.67%
ROCE(5y)9.34%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-5.63%
ROICexc growth 3Y-6.27%
ROICexc growth 5Y-3.36%
OM growth 3Y-8.99%
OM growth 5Y-4.24%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.66%
GM growth 5Y-0.96%
F-Score5
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF 4.13
Debt/EBITDA 2.36
Cap/Depr 54.34%
Cap/Sales 5.46%
Interest Coverage 4.94
Cash Conversion 81.47%
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.02
Altman-Z 2.43
F-Score5
WACC10.24%
ROIC/WACC0.64
Cap/Depr(3y)73.38%
Cap/Depr(5y)82.63%
Cap/Sales(3y)6.31%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-0.39%
EPS 3Y-2.61%
EPS 5Y4.78%
EPS Q2Q%-10.15%
EPS Next Y6.87%
EPS Next 2Y8.98%
EPS Next 3Y8%
EPS Next 5Y8.7%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y0.33%
Revenue growth 5Y6.55%
Sales Q2Q%-0.83%
Revenue Next Year1.7%
Revenue Next 2Y3.17%
Revenue Next 3Y3.18%
Revenue Next 5Y3.26%
EBIT growth 1Y-8.84%
EBIT growth 3Y-8.7%
EBIT growth 5Y2.04%
EBIT Next Year26.23%
EBIT Next 3Y12.9%
EBIT Next 5Y7.36%
FCF growth 1Y3.37%
FCF growth 3Y20.69%
FCF growth 5Y6.41%
OCF growth 1Y0.42%
OCF growth 3Y5.98%
OCF growth 5Y6.18%

CHARLES RIVER LABORATORIES / CRL FAQ

What is the fundamental rating for CRL stock?

ChartMill assigns a fundamental rating of 4 / 10 to CRL.


What is the valuation status of CHARLES RIVER LABORATORIES (CRL) stock?

ChartMill assigns a valuation rating of 5 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.


How profitable is CHARLES RIVER LABORATORIES (CRL) stock?

CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.


Can you provide the expected EPS growth for CRL stock?

The Earnings per Share (EPS) of CHARLES RIVER LABORATORIES (CRL) is expected to grow by 6.87% in the next year.